Table 4.

Mortality risk with CABG compared to PCI

Group	Crude HR	95% CI	P Value	Adjusted HR	95% CI	P Value
Overall (n=3993)	0.93	0.77, 1.12	0.43	0.92	0.76, 1.11	0.38
Preserved kidney Function (n=3467)	0.92	0.74, 1.13	0.42	0.90	0.73, 1.11	0.33
Stage 3-5 CKD (n=526)	1.01	0.68, 1.49	0.98	0.99	0.67, 1.46	0.96
Stage 3a CKD (n=389)	0.87	0.52, 1.45	0.60	0.79	0.47, 1.33	0.39
Stage 3b-5CKD (n=137)	1.15	0.62, 2.13	0.67	1.29	0.68, 2.46	0.43
CKD with multi-vessel disease* (n=419)	1.16	0.77, 1.75	0.49	1.10	0.73, 1.67	0.65
CKD with single-vessel disease* (n=107)	0.33	0.07, 1.61	0.17	0.32	0.06, 1.76	0.19
CKD proximal LAD disease* (n=342)	0.88	0.54, 1.43	0.61	0.94	0.57, 1.54	0.80
CKD without proximal LAD disease* (n=185)	1.31	0.67, 2.56	0.43	1.15	0.57, 2.27	0.71

All models were stratified by trial. Multivariable models adjusted for treatment, age, diabetes, prior myocardial infarction, proximal left anterior descending artery disease, ejection fraction <40%, prior revascularization, and multi-vessel.

^*To avoid model overspecification, these subgroup models did not include terms for multi-vessel disease or proximal LAD disease, respectively. CKD-chronic kidney disease. LAD-left anterior descending artery.